A rooftop deck at Variant Bio’s Seattle offices have a view of the city’s landmark Space Needle. (Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease ...

The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

The Seattle-based biotech prioritizes studying ... Ph.D., corporate vice president of global drug discovery at Novo Nordisk, said in the release. “We believe that the likelihood of discovering ...

We spent an afternoon together in a modernist mansion in Copenhagen called Domus Hagedorn, which is owned by Novo Nordisk, the Danish firm that grew from Hagedorn’s lab. “Hagedorn was rather ...

Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with ...